BMS-986020 + Montelukast + Flurbiprofen + Digoxin

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Drug-drug Interaction Study

Conditions

Drug-drug Interaction Study

Trial Timeline

Sep 1, 2014 → Nov 1, 2014

NCT ID

NCT02227173

About BMS-986020 + Montelukast + Flurbiprofen + Digoxin

BMS-986020 + Montelukast + Flurbiprofen + Digoxin is a phase 1 stage product being developed by Bristol Myers Squibb for Drug-drug Interaction Study. The current trial status is completed. This product is registered under clinical trial identifier NCT02227173. Target conditions include Drug-drug Interaction Study.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02227173	Phase 1	Completed	Sep 1, 2014	Nov 1, 2014	Drug-drug Interaction Study

Competing Products

15 competing products in Drug-drug Interaction Study

See all competitors

Product	Company	Stage	Hype Score
EC905 + verapamil	Astellas Pharma	Phase 1	33
rosuvastatin + fidaxomicin	Astellas Pharma	Phase 1	33
enzalutamide + rifampin	Astellas Pharma	Phase 1	33
ASP3652 + Gemfibrozil + Repaglinide	Astellas Pharma	Phase 1	33
napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate	Sumitomo Pharma	Phase 1	33
Pyrotinib Maleate + Efavirenz	Jiangsu Hengrui Medicine	Phase 1	33
SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride	Jiangsu Hengrui Medicine	Phase 1	33
Rifampin + SHR1459	Jiangsu Hengrui Medicine	Phase 1	33
fostamatinib + Microgynon® 30 (Oral contraceptive) + Placebo	AstraZeneca	Phase 1	33
Simvastatin + Voclosporin	Aurinia Pharmaceuticals	Phase 1	28
Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mg	Lexicon Pharmaceuticals	Phase 1	28
pitavastatin + pitavastatin single dose combined with ceftobiprole	Basilea Pharmaceutica	Phase 1	28
elafibranor + CHRONO-INDOCID	Genfit	Phase 1	25
Raxone (idebenone 150 mg) + Midazolam 2,5 mg	Santhera Pharmaceuticals	Phase 1	25
Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QD	Vaxart	Phase 1	25

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved